Loading stock data…
InspireMD (NSPR)
$0.68-0.04 (-5.60%)
Market ClosedLast close Jun 29
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InspireMD, Inc. in the Healthcare sector is trading at $0.68 with a market capitalization of $36M. Wall Street consensus targets $3.67 (3 analysts), implying a +439.5% move over the next 12 months. The stock is currently near its 52-week low of $0.63, remaining 59.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +439.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.40M↑ | $3.15M↑ | $2.52M↑ | $1.78M↑ | $1.53M |
| Gross Profit | $687,000↓ | $1.18M↑ | $864,000↑ | $313,000↑ | $292,000 |
| Operating Income | -$13.98M↓ | -$12.08M↑ | -$13.05M↓ | -$13.02M↓ | -$11.46M |
| Net Income | -$13.69M↓ | -$11.76M↑ | -$12.71M↑ | -$13.15M↓ | -$11.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationall...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-117.64%
Volume
Today's trading volume
46,818
Recent News
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD, Inc. Q1 2026 Earnings Call Summary
Moby summary of InspireMD, Inc.'s Q1 2026 earnings call
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of +15.79% and +25.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
InspireMD (NSPR) Q4 2025 Earnings Transcript
Marvin Slosman: Thank you, and good morning, everyone. As I reflect on our performance over the past several quarters, I'm extremely proud of our team here at InspireMD and enthusiastic about the impact we are having on stroke prevention and the future of an endovascular standard of care, catalyzed by our breakthrough CGuard Prime carotid stent platform. Through the CGUARDIANS FDA clinical trial, along with our numerous multiyear studies of our CGuard implant, we have demonstrated unmatched clinical evidence reflected in the lowest adverse event rates and most durable stroke prevention, enabling our continued focus on achieving market leadership through a stent-first strategy.
InspireMD (NSPR) Q2 2025 Earnings Transcript
Before we review our recent progress and second quarter results, I'd like to take a moment to formally welcome Mike Lawless, our new Chief Financial Officer. Today's call comes just about a month after we received FDA premarket approval for our CGuard Prime Carotid Stent System, the most significant milestone in our company's history to date. Over 3 million people globally have been diagnosed with carotid artery disease with countless others remaining undiagnosed, while only 155,000 are treated annually in the United States.